Hepatic hematoma: A challenging, emergency disease
Executive Summary
Hepatic hematoma (HH) is a complex medical condition characterized by the intrahepatic collection of blood, clots, and necrotic tissue. While often remaining paucisymptomatic or silent for extended periods, HH presents significant emergency risks due to its potential for rupture, infection, or the induction of secondary syndromes. Its etiology is diverse, ranging from blunt trauma and iatrogenic complications of modern interventional procedures to underlying microvascular diseases such as HELLP syndrome.
The pathophysiology of HH is marked by a "self-feeding" mechanism where internal pressure leads to parenchymal ischemia and necrosis, further expanding the hematoma. Advanced imaging—specifically CT and MRI—is essential for distinguishing HH from simple cysts and for identifying life-threatening complications like hepatic compartment syndrome or hemobilia. Management strategies follow a graduated approach: conservative observation for small, stable lesions (<3 cm); interventional radiology for active hemorrhages; and surgical interventions, such as parietal fenestration or hepatic resection, for complex or ruptured cases.
Etiology and Pathogenesis
Hepatic hematoma originates from various triggers that disrupt the liver's dense vascular network. The liver's "triple vasculature" (arterial, afferent venous, and efferent venous) makes it particularly susceptible to intra-parenchymal hemorrhage.
Primary Causes of Intra-Parenchymal Hemorrhage
Trauma: Includes both blunt abdominal trauma and iatrogenic injury.
Iatrogenic Procedures: HH is an increasingly recognized complication of biopsies, arterial embolization, Transjugular Intrahepatic Portosystemic Shunts (TIPS), Endoscopic Retrograde Cholangiopancreatography (ERCP), and percutaneous biliary drainage.
Vascular Disease: Fissuring or rupture of intrahepatic aneurysms or pseudo-aneurysms.
Microvascular Disorders: Conditions such as vasculitis or HELLP syndrome. In HELLP syndrome, endothelial damage in portal venules or hepatic sinusoids creates microhemorrhagic foci that eventually coalesce into a large hematoma.
Pathophysiological Evolution
The progression of an HH is governed by several mechanical and biological factors:
Expansion and Necrosis: HH expands based on the strength of its blood supply. This expansion compresses surrounding liver parenchyma, causing ischemia and necrosis, which in turn facilitates further hematoma growth.
Lack of Encapsulation: In early stages, the absence of a fibrous capsule increases the risk of rupture, especially when internal tension rises (following Laplace’s law).
Diaphragmatic Involvement: HH located near the hepatic dome may involve the diaphragm, potentially expanding into the mediastinum or right hemithorax.
Clinical Complications and Syndromes
Large or progressing hematomas can trigger a cascade of secondary complications, some of which mimic other hepatic pathologies.
Diagnostic Procedures
Diagnostic clarity is often difficult because HH can be asymptomatic or mimic simple hepatic cysts. Accurate diagnosis relies heavily on cross-sectional imaging and clinical history.
Ultrasound (US): Typically shows an anechoic mass at onset. Fast US is critical in emergency "acute abdomen" scenarios to identify intrahepatic masses and peri-hepatic effusion.
Computed Tomography (CT): Displays HH as a hypo-attenuating mass. CT angiography is the gold standard for identifying active arterial bleeding (indicated by stagnating contrast medium) or gas bubbles signifying an abscess.
Magnetic Resonance Imaging (MRI): HH appears strongly hyperintense on T2-weighted or cholangiographic sequences. MRI can also identify internal biliary fistulas through paradoxical reflux of contrast into the HH cavity.
Morphological Characteristics: Depending on location, HH may present in "quarter-moon," biconvex, or biconcave shapes. Unlike tumors, they generally lack internal parietal vegetations.
Management and Therapeutic Strategies
Treatment is determined by the size of the hematoma, the presence of complications, and the hemodynamic stability of the patient.
Conservative and Minimally Invasive Management
Observation: Small (<3 cm) intra-parenchymal hematomas that are asymptomatic and stable may be managed conservatively.
Selective Vascular Embolization: The preferred treatment for active arterial bleeding or secondary hemobilia. Venous hemobilia is more challenging and may require trans-hepatic US-guided or jugular vein catheterization.
Percutaneous Drainage: Used as a "damage control" measure for HH complicated by infection or abscess, especially in unstable patients.
Surgical Interventions
Surgery is indicated for ruptured hematomas, progressive size increases, or cases where conservative measures fail.
Parietal Fenestration and Omentoplasty: Involves the resection of the "salient dome" of the hematoma. This is suitable for HH with plastic walls capable of remodeling.
Total or Subtotal Peri-cystectomy: Indicated when a rigid fibrous capsule is present. This follows the dissection plane just outside the HH to prevent residual cavities and recurrence.
Hepatic Resection: Necessary for hematomas with complete intrahepatic development or those involving proximal bile ducts in persistent biliary fistulas.
Emergency Laparotomy: Mandatory for ruptured HH to treat peritonitis, drain the cavity, and perform partial parietal resection.
Conclusion
Hepatic hematoma is a multifaceted and challenging disease that requires high clinical suspicion, particularly following abdominal trauma or invasive hepatic procedures. Its ability to trigger secondary syndromes—such as compartment syndrome or Budd-Chiari-like manifestations—highlights the need for detailed diagnostic study. While non-invasive treatments are increasingly common, surgical intervention remains a cornerstone for managing acute complications and preventing recurrence in cases with complex pathology.
